But it remains to be seen how long this can continue because of dwindling sales of its inflammatory disease drug Remicade and a looming threat to Zytiga. Zytiga (abiraterone), approved since 2011 ...

Janssen's prostate cancer drug Zytiga should not be used earlier in patients, because it would not be cost effective, says NICE. Draft guidance from the cost effectiveness watchdog says Zytiga ...

The large food effect of Zytiga is also avoided ... with only mild-to-moderate side effects reported. Currently, the drug is in Phase II stage of its development for the treatment of prostate ...

In a live event, Ganesh V. Raj, MD, PhD, discussed the drug-drug interactions and outcomes by disease volumes across ARPI ...